With a strong track record of drug discovery and development, Alderley Park is home to over a variety of CROs specialising in: Pre-clinical, Clinical, Safety/Tox, CMC/Formulation, Regulatory, Chemistry and Proteins as well as many therapeutics companies specialising in Oncology and Anti-infectives.
Medicines Discovery Catapult
As a national centre of applied R&D expertise, the Medicines Discovery Catapult promotes and supports the discovery of new medicines in the UK through collaborative projects. These include working with industry, academic teams, technology experts, charities, regulators and others.
As such, it helps accelerate the discovery of innovative, fast-to-patient drugs by transforming great ideas into commercial products and services for the wider health and wealth of the country.
For further information about the Medicines Discovery Catapult visit the website here.
Centre for Antimicrobial Resistance
The Antimicrobial Resistance (AMR) Centre at Alderley Park is playing a key role in the UK’s response to the global threat from Antimicrobial Resistance. As a joint private-public venture, it aims to get all new antimicrobial drugs and diagnostics to market in the shortest possible time through a fully integrated development capability, offering translational R&D from pre-clinical hits through to clinical proof of concept.
For further information about the Centre for Antimicrobial Resistance visit the website here.